Leptospirosis Multi-Epitope Vaccine Candidate Data

Aggregating results from a study employing comparative pan-genomic analysis and reverse vaccinology to design a multi-epitope vaccine (MEV) against Leptospira. The research includes in silico analyses, experimental validation with hyperimmune and clinical sera, and mouse immunization results. The dataset is provided as an XLSX file with an unknown number of rows and columns.

Use Cases

• Analyze conserved potential vaccine candidates (PVCs) identified through pan-genomic analysis for epitope selection.
• Evaluate the immunogenic potential and stability of the multi-epitope vaccine (MEV) construct from in silico validation data.
• Assess cross-reactivity of anti-MEV antibodies with multiple pathogenic Leptospira serovars using serological data.
• Examine macrophage activation and proinflammatory cytokine production data following MEV stimulation in vitro.
• Model the humoral and T-cell response data from mouse immunization trials to predict vaccine efficacy.

Strengths

• Data is derived from an integrated strategy combining soft-core genome-wide antigen prioritization with structural validation.
• Experimental evaluation includes both innate and adaptive immune responses, providing a multi-faceted view.
• The vaccine construct incorporates a TLR4 agonist (APPHALS) to enhance immune activation, a specific design feature.

Limitations

• The dataset is very small at 67.8 KB, indicating limited scope and likely a summary of results rather than raw experimental data.
• The number of rows, columns, and sample data are unknown, limiting immediate analytical utility.
• The data is specific to a single research project's vaccine candidate, limiting generalizability.

Provenance

Source

figshare, authored by Mohd Abdullah.

Collection Method

Generated through comparative pan-genomic analysis, reverse vaccinology, and subsequent in silico and experimental validation.

Freshness

Last updated on 2026-03-20.